Soda Health vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 35)
Soda Health logo

Soda Health

EmergingHealthcare

Supplemental Health Benefits Administration & Health Equity Platform

Soda Health is a healthcare technology platform managing supplemental benefits (OTC, food, fitness, flex cards) for Medicare Advantage and Medicaid members; bridges health plan payments with retail and service providers to reduce health inequity;

AI VisibilityBeta
Overall Score
D35
Category Rank
#537 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
34
Gemini
38

About

Soda Health is a healthcare technology company founded in 2020 and headquartered in Atlanta, Georgia, that operates a supplemental benefits administration platform for health insurers — primarily Medicare Advantage and Medicaid plans. As health plans increasingly offer non-medical supplemental benefits (such as over-the-counter health product allowances, food and produce benefits, fitness memberships, and flexible spending cards) to address social determinants of health, Soda Health's platform manages the administration, member experience, and retail fulfillment of these benefits. The platform bridges the gap between health plan benefit design and the retail and service network where members actually use their benefits — simplifying what has historically been a fragmented, confusing experience for vulnerable populations.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

35
Overall Score
93
#537
Category Rank
#1
85
AI Consensus
80
stable
Trend
up
35
ChatGPT
94
34
Perplexity
89
38
Gemini
94
32
Claude
92
37
Grok
98

Key Details

Category
Supplemental Health Benefits Administration & Health Equity Platform
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.